Published in Prostate on December 07, 2011
DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet (2012) 3.33
Biomarkers in prostate cancer: what's new? Curr Opin Oncol (2014) 1.16
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies. J Urol (2014) 1.10
Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05
A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. BMC Urol (2012) 0.94
Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One (2013) 0.90
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer. BMC Cancer (2012) 0.84
Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma. PLoS One (2015) 0.84
Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol (2012) 0.84
Budget impact model: epigenetic assay can help avoid unnecessary repeated prostate biopsies and reduce healthcare spending. Am Health Drug Benefits (2013) 0.83
Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. Prostate Cancer (2012) 0.83
Reduced Rate of Repeated Prostate Biopsies Observed in ConfirmMDx Clinical Utility Field Study. Am Health Drug Benefits (2014) 0.83
Characterization of a Gene Expression Signature in Normal Rat Prostate Tissue Induced by the Presence of a Tumor Elsewhere in the Organ. PLoS One (2015) 0.81
Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. Prostate (2015) 0.80
Characterization and directed evolution of a methyl-binding domain protein for high-sensitivity DNA methylation analysis. Protein Eng Des Sel (2015) 0.80
DNA Methylation-Guided Prediction of Clinical Failure in High-Risk Prostate Cancer. PLoS One (2015) 0.79
Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. Curr Gerontol Geriatr Res (2014) 0.78
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Diagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer. PLoS One (2014) 0.77
Mechanisms of epigenetic regulation of leukemia onset and progression. Adv Immunol (2013) 0.77
DNA Methylation-Mediated Downregulation of DEFB1 in Prostate Cancer Cells. PLoS One (2016) 0.77
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate (2016) 0.76
Genome-wide epigenomic profiling for biomarker discovery. Clin Epigenetics (2016) 0.75
CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Trans Am Clin Climatol Assoc (2016) 0.75
Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Sci Rep (2017) 0.75
Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach. J Transl Med (2016) 0.75
Correlation of HOXD3 promoter hypermethylation with clinical and pathologic features in screening prostate biopsies. Prostate (2014) 0.75
GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications. Dis Markers (2016) 0.75
Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment. Biomed Res Int (2013) 0.75
Cell-free DNA as a diagnostic marker for cancer: current insights. Onco Targets Ther (2016) 0.75
Clinically relevant genetic characterization of prostate tumors: how close are we to the goal? Korean J Urol (2015) 0.75
[Molecular biomarkers and prognostic factors for prostate cancer]. Urologe A (2017) 0.75
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell (2010) 16.12
A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet (2007) 9.47
Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet (2004) 7.78
Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res (2002) 7.09
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med (2008) 5.87
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med (2006) 5.80
A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet (2002) 5.38
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov (2011) 4.60
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol (2008) 4.32
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res (2006) 4.15
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet (2005) 3.66
Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet (2006) 3.54
Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genet (2007) 3.39
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08
Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res (2006) 3.05
Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05
Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol (2002) 3.00
Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98
Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biol (2008) 2.85
Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res (2002) 2.84
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
A systematic profile of DNA methylation in human cancer cell lines. Cancer Res (2003) 2.75
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
Telomere length and cardiovascular risk factors in a middle-aged population free of overt cardiovascular disease. Aging Cell (2007) 2.62
Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer (2004) 2.61
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol (2008) 2.51
Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol (2003) 2.42
GATA-4 and GATA-5 transcription factor genes and potential downstream antitumor target genes are epigenetically silenced in colorectal and gastric cancer. Mol Cell Biol (2003) 2.42
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
PubMeth: a cancer methylation database combining text-mining and expert annotation. Nucleic Acids Res (2007) 2.41
Evaluation of non-formalin tissue fixation for molecular profiling studies. Am J Pathol (2002) 2.38
Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst (2002) 2.38
Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell (2003) 2.38
SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood (2002) 2.34
Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. Am J Surg Pathol (2006) 2.34
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin Cancer Res (2003) 2.28
Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology (2010) 2.27
N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. J Natl Cancer Inst (2009) 2.22
Should intervening benign tissue be included in the measurement of discontinuous foci of cancer on prostate needle biopsy? Correlation with radical prostatectomy findings. Am J Surg Pathol (2011) 2.20
BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol (2010) 2.18
Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program. J Urol (2009) 2.17
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
Epigenetic inactivation of the canonical Wnt antagonist SRY-box containing gene 17 in colorectal cancer. Cancer Res (2008) 2.16
Transurethral resection specimens of the bladder: outcome of invasive urothelial cancer involving muscle bundles indeterminate between muscularis mucosae and muscularis propria. Urology (2010) 2.08
Genomic and epigenomic integration identifies a prognostic signature in colon cancer. Clin Cancer Res (2011) 2.06
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol (2006) 2.05
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst (2006) 2.05
Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res (2003) 2.04
Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res (2003) 2.03
Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res (2003) 2.03
Impact of surgical delay on long-term cancer control for clinically localized prostate cancer. J Urol (2004) 1.95
Villous adenoma of the urinary tract: a lesion frequently associated with malignancy. Hum Pathol (2002) 1.95
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate (2009) 1.95
Spindle cell lesions of the adult prostate. Mod Pathol (2007) 1.94
Promoter hypermethylation of resected bronchial margins: a field defect of changes? Clin Cancer Res (2004) 1.93
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol (2010) 1.87
Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy. J Urol (2011) 1.82
Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer. J Urol (2012) 1.80
Defining a gene promoter methylation signature in sputum for lung cancer risk assessment. Clin Cancer Res (2012) 1.80
Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol (2005) 1.80
Epithelial proliferations in prostatic stromal tumors of uncertain malignant potential (STUMP). Am J Surg Pathol (2011) 1.80
Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res (2009) 1.80
Malignant solitary fibrous tumor of the kidney: report of a case and comprehensive review of the literature. Arch Pathol Lab Med (2006) 1.79
The fundamental role of epigenetics in hematopoietic malignancies. Blood Rev (2005) 1.79
Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol (2012) 1.78
Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis (2003) 1.78
GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clin Cancer Res (2009) 1.78
Primary thyroid-like follicular carcinoma of the kidney: report of 6 cases of a histologically distinctive adult renal epithelial neoplasm. Am J Surg Pathol (2009) 1.78
Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet (2003) 1.77
Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol (2009) 1.77
hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Res (2007) 1.77
Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res (2007) 1.76
Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen?: a microsatellite analysis of specimen identity. Am J Surg Pathol (2005) 1.75
Interobserver reproducibility in the diagnosis of invasive micropapillary carcinoma of the urinary tract among urologic pathologists. Am J Surg Pathol (2010) 1.73
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Evaluation of whole slide image immunohistochemistry interpretation in challenging prostate needle biopsies. Hum Pathol (2008) 1.72
Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol (2007) 1.72